Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineered NK92 cell-derived exosomes inhibit ovarian cancer progression by degrading <i>GPRC5A</i>.

Frontiers in immunology·2025
Same author

CAR Cell-Derived Exosomes in Cancer Therapy: Biogenesis, Engineering Strategies and Antitumor Mechanisms.

International journal of molecular sciences·2025
Same author

Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications.

Molecular cancer·2024
Same author

Engineered exosomes in emerging cell-free therapy.

Frontiers in oncology·2024
Same author

The Role of Cytoskeleton Protein 4.1 in Immunotherapy.

International journal of molecular sciences·2023
Same author

Exosomal circTUBGCP4 promotes vascular endothelial cell tipping and colorectal cancer metastasis by activating Akt signaling pathway.

Journal of experimental & clinical cancer research : CR·2023

Related Experiment Video

Updated: Jun 14, 2025

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

9.5K

Targeting m7G-enriched circKDM1A prevents colorectal cancer progression.

Zhenqiang Sun1,2,3, Yanxin Xu4,5,6, Chaohua Si7,8

  • 1Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. fccsunzq@zzu.edu.cn.

Molecular Cancer
|August 30, 2024
PubMed
Summary

METTL1 enzyme modifies circRNAs with m7G, enhancing colorectal cancer (CRC) progression by stabilizing circKDM1A and activating the AKT pathway. This study reveals a key mechanism in CRC development.

Keywords:
AKT pathwayColorectal cancer (CRC)M7G modificationcircRNA

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

843

Related Experiment Videos

Last Updated: Jun 14, 2025

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

9.5K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

843

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Biology

Background:

  • Circular RNAs (circRNAs) are implicated in colorectal cancer (CRC), but the mechanisms driving their aberrant expression remain unclear.
  • RNA modifications, such as N6-methyladenosine (m6A), are increasingly recognized for their roles in gene regulation and cancer.

Purpose of the Study:

  • To investigate the role of m7G RNA modifications in circRNAs within colorectal cancer.
  • To elucidate the mechanism by which METTL1 influences circRNA stability and CRC progression.
  • To identify specific circRNAs regulated by METTL1 and their downstream effects on CRC.

Main Methods:

  • Analysis of m7G modification enrichment in circRNAs from CRC samples.
  • Identification of METTL1 as the m7G methyltransferase for circRNAs, with GG motif preference.
  • Functional assays (in vitro and in vivo) to assess the impact of circKDM1A and its m7G modification on CRC cell proliferation, invasion, and migration.
  • Western blotting and qRT-PCR to examine the activation of the AKT pathway and PDK1 expression.

Main Results:

  • m7G modifications are enriched in certain circRNAs in CRC, catalyzed by METTL1 with a preference for the GG motif.
  • METTL1 promotes CRC progression by stabilizing circKDM1A via m7G modification, enhancing proliferation, invasion, and migration.
  • CircKDM1A activates the AKT pathway by upregulating PDK1, thereby promoting CRC progression; this effect is diminished upon m7G site mutation.

Conclusions:

  • METTL1-mediated m7G modification of circRNAs is a crucial mechanism in colorectal cancer progression.
  • The identified circKDM1A acts as an oncogene in CRC by stabilizing through m7G modification and activating the AKT/PDK1 pathway.
  • This study uncovers a novel regulatory axis involving METTL1, m7G-modified circRNAs, and the AKT pathway in CRC pathogenesis.